VivoSeq
Other

Natural Killer Cell

0

Pipeline Programs

8

Active Trials

2

Companies Involved

Natural Killer Cell is an early-stage landscape with 0 programs across 2 companies. The most active players are NKGen Biotech, Inc., CHABiotech CO., Ltd.

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

58/100

Attrition Rate

20/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

25

clinical trials

Completed7 · 28%
Unknown status5 · 20%
Terminated4 · 16%
Recruiting4 · 16%
Not yet recruiting2 · 8%
Active, not recruiting2 · 8%
Other1 · 4%

Trial Activity

25 trials

Effect of Prednisolone Treatment on Uterine Natural Killer Cells
Recruiting··Phase 3·NCT03902912·84 enrolled
In Vitro Expanded Autologous Invariant Natural Killer Cells in Cancer
Completed··Phase 1·NCT00631072·9 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)